Related Experiment Video
Updated: Jun 29, 2025

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
Published on: May 31, 2024
Antibiotic Use in the 12 Months Prior to Ileal Pouch-Anal Anastomosis Increases the Risk for Pouchitis
Edward L Barnes1, Anastasia Karachalia Sandri2, Hans H Herfarth1
1Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Insights
Antibiotic exposure before ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis (UC) increases the risk of developing pouchitis. This finding highlights a potential modifiable risk factor for this common post-surgical complication.
Area of Science:
- Gastroenterology
- Surgical Complications
- Inflammatory Bowel Disease Research
Background:
- Pouchitis is the most frequent complication following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC).
- Clinical and environmental risk factors contributing to pouchitis development are not well understood.
- Identifying these factors is crucial for managing post-IPAA complications.
Purpose of the Study:
- To investigate the association between specific clinical factors and the incidence of pouchitis.
- To determine if antibiotic exposure, NSAID use, or appendectomy influences pouchitis risk post-IPAA.
- To provide evidence for potential preventative strategies.
Main Methods:
- A population-based cohort study was conducted in Denmark, including adult UC patients who underwent IPAA between 1996 and 2020.
- Cox proportional hazard modeling was employed to analyze the impact of pre-operative antibiotic, NSAID exposure, and appendectomy on acute pouchitis diagnosis within two years.
- Adjustments were made for anti-tumor necrosis factor alpha use and patient sex.
Main Results:
- Out of 1616 patients, 46% developed pouchitis within two years of IPAA.
- Antibiotic exposure in the 12 months preceding IPAA significantly increased pouchitis risk (aHR, 1.41).
- The risk escalated with the number of antibiotic courses (1-2 courses: aHR, 1.30; 3+ courses: aHR, 1.77), while NSAID use and appendectomy showed no significant association.
Conclusions:
- Pre-operative antibiotic exposure within a year of IPAA is a significant risk factor for acute pouchitis in UC patients.
- This finding suggests a potential target for intervention to reduce pouchitis incidence.
- Further research into microbial changes in at-risk patients is recommended for early intervention strategies.
Background & Aims:
Pouchitis is the most common complication after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC); however, clinical and environmental risk factors for pouchitis remain poorly understood. We explored the relationship between specific clinical factors and the incidence of pouchitis.
Methods:
We established a population-based cohort of all adult persons in Denmark undergoing proctocolectomy with IPAA for UC from 1996-2020. We used Cox proportional hazard modeling to assess the impact of antibiotic, nonsteroidal anti-inflammatory drug (NSAID) exposure, and appendectomy on diagnosis of acute pouchitis in the first 2 years after IPAA surgery.
Results:
Among 1616 eligible patients, 46% developed pouchitis in the first 2 years after IPAA. Antibiotic exposure in the 12 months before IPAA was associated with an increased risk of pouchitis (adjusted hazard ratio [aHR], 1.41; 95% confidence interval [CI], 1.22-1.64) after adjusting for anti-tumor necrosis factor alpha use and sex. Compared with persons without any antibiotic prescriptions in the 12 months before IPAA, the risk of pouchitis was increased in those with 1 or 2 courses of antibiotics in that period (aHR, 1.30; 95% CI, 1.11-1.52) and 3 or more courses (aHR, 1.77; 95% CI, 1.41-2.21). NSAID exposure in the 12 months before IPAA and appendectomy were not associated with risk of acute pouchitis (P = .201 and P = .865, respectively).
Conclusions:
In this population-based cohort study, we demonstrated that antibiotic exposure in the 12 months before IPAA is associated with an increased risk of acute pouchitis. Future prospective studies may isolate specific microbial changes in at-risk patients to drive earlier interventions.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

